Testing a new drug with radiation for recurrent gynecologic cancers

Plain-English translation of NCT03968406 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a medication called combined with radiation therapy for gynecologic cancers (cancers of the ovaries, cervix, uterus, and related organs) that have returned after previous treatment. The study aims to find the right dose of the medication and understand how well this combination works. Researchers will carefully monitor your safety and quality of life throughout the study.

Standard treatments for recurrent gynecologic cancers don't work well for everyone. This trial explores whether combining this medication with radiation therapy might help patients whose cancers have come back, offering a new treatment option for people with limited choices.

Do you qualify?

You likely qualify if…

you have been diagnosed with recurrent ovarian, cervical, fallopian tube, endometrial, vaginal, or primary peritoneal cancer
your cancer is located in the abdomen or pelvis and can be treated with radiation
your blood work shows healthy levels of red cells, white cells, and platelets
your liver and kidney function are adequate based on recent blood tests
you are able to take care of yourself independently or with minimal help (ECOG score of 0–1)
you have a life expectancy of at least 16 weeks

You likely don't qualify if…

you are currently pregnant or breastfeeding
you have received chemotherapy or other cancer drugs in the past three weeks
you have signs of bone marrow disease or blood disorders on recent blood tests
you have severe liver or kidney problems
you are unable or unwilling to use two forms of effective birth control during the study

What participation looks like

You will take the medication by mouth once daily for up to 8 weeks, starting about one to two weeks before radiation begins. You'll receive radiation therapy five days per week (Monday–Friday) for up to 7 weeks. You'll have regular check-up visits during treatment and follow-up appointments at 1, 3, 6, 9, and 12 months after treatment ends, with additional visits every 6 months for up to one year. Blood tests will monitor your safety throughout the study.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(2 sites)

United States

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

M D Anderson Cancer Center, Houston, Texas